



July 21, 2026

The Honorable Mike Johnson
Speaker of the House
568 Cannon House Office Building,
Washington, DC 20515

The Honorable Hakeem Jeffries
House Minority Leader
2267 Rayburn House Office Building,
Washington, DC 20515

The Honorable Steve Scalise
House Majority Leader
266 Cannon HOB, Washington, District of
Columbia 20515

The Honorable Tom Emmer
House Majority Whip
326 Cannon House Office Building,
Washington, District of Columbia 20515

The Honorable Brett Guthrie
Chair, House Energy & Commerce
Committee
2161 Rayburn House Office Building,
Washington, DC, 20515

The Honorable Frank Pallone
Ranking Member, House Energy &
Commerce Committee
2107 Rayburn House Office Building,
Washington, DC, 20515

The Honorable Jason Smith
Chair, House Ways & Means Committee
1011 Longworth House Office Building,
Washington, DC 20515

The Honorable Richard Neal
Ranking Member, House Ways & Means
Committee
372 Cannon House Office Building,
Washington, DC 20515

RE: Advancing Women's Cardiac Health and Broader Innovation Through Genetically
Targeted Technologies – Invest in Research and Advance the MINI Act (H.R.1672)

Dear Speaker Johnson, Majority Leader Scalise, Majority Whip Emmer, Chairman Guthrie,
Chairman Smith, Minority Leader Jeffries, Ranking Member Pallone, and Ranking Member
Neal:

We, the undersigned organizations, write to express our strong support for investment in genetically targeted technologies (GTTs) that stand to advance women's health.

Cardiovascular disease has taken the lives of far too many women, causing [1 in 3 deaths](#) each year. By addressing the drivers of cardiac disease risk, GTTs hold unique promise in changing this trend and promoting cardiac health, especially among women.

Notably, GTTs are also positioned to support many more disease states that women navigate as patients and as caregivers, including:

- **Rare Diseases:** Millions of people worldwide are affected by rare diseases; however, these diseases disproportionately impact women due to diagnostic delays, unique genetic susceptibilities, and gender gaps in medical research. For example, [4 out of 5 patients](#) with autoimmune disorders, many of which are classified as rare, are women. Beyond higher prevalence, studies consistently indicate that the majority of rare disease caregivers are women. Despite this increased burden, sex-specific rare disease research and therapeutic development remains [limited](#).
- **Neurological Conditions:** Across a wide range of prominent neurological conditions such as Alzheimer's, Parkinson's, multiple sclerosis, and migraine, women face disproportionate disease risk, disease burden, and caregiving responsibilities. And yet again, innovation for these conditions [does not reflect the burden](#) of disease.
- **Pediatric Chronic Diseases:** The prevalence of pediatric chronic diseases has risen to [nearly 30%](#) of people ages 5 to 25 in the last 20 years. With mothers serving as the primary advocate for their children, innovative therapeutics that can address the complex care needs of a child living with a chronic disease can make a real difference for children and mothers alike.

To realize the potential of GTTs, however, federal policy must support its research and innovation pipeline. Congress can start by supporting robust funding for the National Institutes of Health (NIH) to lead basic science discovery research and clinical testing for GTTs. Such an investment ensures that the NIH is positioned to pave the way for breakthroughs in GTT development as it has done for decades.

Congress should also advance the ***Maintaining Investments in New Innovation (MINI) Act*** ([H.R.1672](#)). This legislation would promote continued investment in groundbreaking treatments for cardiovascular health, rare diseases, neurological conditions, and pediatric diseases by giving GTTs the same 11-year timeline before drug price negotiation that biologics receive, instead of the current, shorter seven-year timeline. In this targeted way, this legislation promotes continued investment in this Nobel Prize-winning scientific innovation and makes better care for women and their loved ones possible.

We are committed to working with you to advance policies that prioritize women's health, support caregivers, and strengthen our nation's commitment to medical innovation, including GTTs. Thank you for your leadership and dedication to this important issue. We look forward to your support and to continued collaboration.

Sincerely,

healthywomen

<https://www.healthywomen.org/>

List of Signers:

ALS Association
AIMED Alliance
Alliance for Patient Access (AfPA)
American Brain Coalition
Amputee Coalition of America
Amyloidosis Army Kansas City
Association of Black Cardiologists, Inc. (ABC)
Autoimmune Association
Black Heart Association
Caregiver Action Network
EveryLife Foundation for Rare Diseases
Family Heart Foundation
Foundation for Sarcoidosis Research (FSR)
Heart Valve Voice US
Hypertrophic Cardiomyopathy Association
KIF1A.ORG
Mended Hearts
National Association of Hispanic Nurses (NAHN)
National Black Nurses Association, Inc
National Grange
National Headache Foundation
National Organization for Rare Disorders
National Hispanic Health Foundation (NHHF)
Partnership to Advance Cardiovascular Health
Preventive Cardiovascular Nurses Association (PCNA)
RetireSafe
Sjögren's Foundation
Spina Bifida Association
StopAfib.org
Vasculitis Foundation
WomenHeart